Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTyratech Regulatory News (TYR)

  • There is currently no data for TYR

Director/PDMR Shareholding

19 Sep 2016 15:59

RNS Number : 2403K
TyraTech, Inc.
19 September 2016
Β 

For immediate release: 19 September 2016

Β 

TyraTech, Inc.

Β 

("TyraTech" or the "Company")

Β 

PDMR Dealings

TyraTech, Inc. (AIM: TYR and TYRU), a life sciences technology company focused on nature-derived insect and parasite control products, announces thatΒ Erica Boisvert, Chief Financial Officer, purchased 100,000 ordinary shares in the Company on 14th September 2016 at a price of USD 0.0285 per ordinary share.

Following this transaction, Ms. Boisvert is interested in 600,000 ordinary shares in the Company representing 0.16 per cent of TyraTech issued share capital (voting rights), as per the following table:-

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Erica Boisvert

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification /Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

TyraTech Inc.

b)

Legal Entity Identifier

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Β 

Identification code

Β 

Common shares of USD 0.001 per share par value

Β 

Β TYR.LΒ 

b)

Nature of the transaction

Purchase

c)

Currency

USD

d)

Price(s) and volume(s)

Price(s)

Volume(s)

$0.0467

$.0464

$0.0285

30,000 (1)

470,000 (2)

100,000 (3)

e)

Aggregated information

- Aggregated volume

- Aggregated price

- Aggregated total

Β 

600,000

0.0434

$26,059

f)

Date of the transaction

(1) 2016-02-04

(2) 2016-02-05

(3) 2016-09-14

g)

Place of the transaction

London Stock Exchange, AIM XLON

Β 

*-ends*-

Β 

For further information please visit: www.tyratech.com or contact:

Β 

TyraTech Inc.

Bruno Jactel, Chief Executive Officer

Erica Boisvert, Chief Financial Officer

Β 

Tel: +1 919 415 4340

Tel: +1 919 415 4287

Β 

SPARK Advisory Partners Limited (Nominated Adviser)

Matt Davis / Mark Brady

Β 

Β 

Β Tel: +44 20 3368 3551

Β 

Allenby Capital Limited (Joint Broker)

Chris Crawford

Β 

Β 

Tel: +44 20 3328 5656

Β 

Whitman Howard Limited (Joint Broker)

Ranald McGregor-Smith

Β 

Β 

Tel: +44 20 7659 1234

Β 

Belvedere Communications (PR)

John West / Kim van Beeck

Β 

Β 

Tel: +44 20 3567 0510

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
DSHLLMITMBABBRF
Date   Source Headline
29th Sep 20107:00 amRNSInterim Results
9th Sep 20109:46 amRNSNotice of Interim Results
25th Aug 20104:50 pmRNSUnrestricted Trading Line Completed
5th Aug 20107:00 amRNSBoard Change
29th Jul 20102:40 pmRNSMajor Interest in Shares
19th Jul 20107:00 amRNSEstablishing Unrestricted Trading Line
9th Jul 201012:41 pmRNSResult of AGM and Board Changes
23rd Jun 20104:06 pmRNSMajor Interest in Shares
22nd Jun 20107:00 amRNSResults for the year ended 31 December 2009
21st May 20105:35 pmRNSDirectors' Disclosure
19th May 20105:15 pmRNSResult of Special Meeting
18th May 20107:00 amRNSUpdate to Fundraising
10th May 20107:00 amRNSFundraising and Trading Update
29th Apr 20107:00 amRNSProspective fundraising of approximately £1m
24th Feb 20107:00 amRNSPreliminary Results
4th Feb 20105:41 pmRNSAward of Share Options
4th Feb 20107:00 amRNSExpanded Terminix Agreement
5th Jan 20107:00 amRNSBoard Changes
24th Nov 20097:00 amRNSTrading Update
11th Nov 20097:00 amRNSDirector Share Purchase
9th Nov 20097:00 amRNSArysta Insecticide Product Launch
5th Oct 20097:00 amRNSKraft Milestone and Contract
21st Sep 20093:41 pmRNSDirector Share Purchase
16th Sep 20097:01 amRNSBoard Changes
16th Sep 20097:01 amRNSChange of Auditor
16th Sep 20097:00 amRNSInterim Results
10th Sep 20097:00 amRNSClarke Partnership
19th Aug 20097:00 amRNSStrategic Partnership Agreement
28th Jul 20097:00 amRNSNew Product Launch
23rd Jul 20097:00 amRNSTrading Update
22nd Jun 20092:03 pmRNSAnnual Report and Accounts
21st May 200912:15 pmRNSAGM Statement
20th May 20097:00 amRNSExpanded Agreement with Terminix
20th Apr 20097:00 amRNSTerminix First Shipment
16th Apr 20096:02 pmRNSDirectors Share Purchase
15th Apr 20096:20 pmRNSDIRECTORS SHARE PURCHASE
14th Apr 20095:44 pmRNSDirectors Share Purchase
9th Apr 20095:17 pmRNSDirector Share Dealings
7th Apr 20095:00 pmRNSCorrected Notice of AGM
1st Apr 20097:06 amRNSPreliminary Results
30th Mar 20097:00 amRNSNew product Launches
20th Mar 20097:00 amRNSNotice of Preliminary Results
27th Jan 20097:00 amRNSShare Buy Back Transaction
16th Jan 20097:04 amRNSOptions Award
16th Jan 20097:02 amRNSShare Buy Back
16th Jan 20097:00 amRNSSalary Reductions
14th Jan 20097:00 amRNSNew Joint Venture - TyraChem
23rd Dec 20087:00 amRNSProgress with Kraft Foods Partnership
24th Nov 20087:00 amRNSAgreement Signed with Terminix
20th Oct 20087:00 amRNSSummons from Molecular Securities, Inc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.